Log In
Print
BCIQ
Print
Print this Print this
 

VB-201

  Manage Alerts
Collapse Summary General Information
Company VBL Therapeutics Ltd.
DescriptionToll-like receptor 2 (TLR2) and TLR4 antagonist that inhibits production of proinflammatory cytokines IL-12 and IL-23
Molecular Target Toll-like receptor 2 (TLR2) ; Toll-like receptor 4 (TLR4)
Mechanism of ActionInterleukin-12 (IL-12) inhibitor; Interleukin-23 (IL-23) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAtherosclerosis
Indication DetailsTreat atherosclerosis
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today